Kiniksa Pharmaceuticals competitors

Mr. Krishnan brings many years of experience in the life sciences industry, having held key executive roles at several companies including, most notably, his tenure as Chief Financial Officer, Chief Operating Officer, and board member of New River Pharmaceuticals, Inc. (previously traded on NASDAQ prior to its acquisition by Shire plc in 2007). Previously, he served as a Senior Managing Director of Third Security, LLC between 2001 and 2008 and as a board member of Biotie Therapies Oyj (BTH1V:Helsinki) between 2008 and 2009. Mr. Krishnan started his career as an engineer with E.I. Dupont de Nemours in Wilmington, Delaware. He received a B.S. in Mechanical Engineering from the Indian Institute of Technology, a M.S. in Engineering from UT, Ohio, and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania.

Mr. Stephen Zaruby W. is a President and Chief Executive Officer at AURINIA PHARMACEUTICALS INC and is based in United States.

Brent Furse has served as a Director and our Chief Executive Officer and President since June 2016. Prior to coming to VERO Biotech, Mr. Furse was a key member of The Medicines Company leadership team where he joined in 2000 pre-IPO and served as a section 16 Officer. Brent has held various leadership positions including Executive Vice President, Chief Operating Officer, Chief Commercial Officer, Vice President, and General Manager Interventional Medicine, Vice President Surgery and Perioperative Care, and Vice President of Sales and Marketing. He was responsible for the launch and success of their flagship product Angiomax, as well as countless successful partnerships and operational excellence. In addition to his success at The Medicines Company, Brent has held leadership positions with Centers for Disease Control and Prevention, Bristol-Myers Squibb, and Schering Plough Corporation, and serves on the board of Anthera Pharmaceuticals, The Special Olympics, and Salus Tele-health.